Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C46H80N2O13 |
Molecular Weight | 869.133 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 19 / 19 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]4(O[C@H]1[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@H](CO[C@@H]3O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]3OC)[C@@H](CC)OC(=O)C[C@@H](O)[C@@H]1C)O[C@H](C)[C@@H](O)[C@@H]([C@H]4O)N(C)C
InChI
InChIKey=JTSDBFGMPLKDCD-XVFHVFLVSA-N
InChI=1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3/b15-14+,25-19+/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,46-/m1/s1
DescriptionSources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm115928.pdfCurator's Comment: description was created based on several sources, including
http://www.fao.org/docrep/W4601E/w4601e0e.htm
http://www.merckvetmanual.com/mvm/pharmacology/antibacterial_agents/macrolides.html
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm115928.pdf
Curator's Comment: description was created based on several sources, including
http://www.fao.org/docrep/W4601E/w4601e0e.htm
http://www.merckvetmanual.com/mvm/pharmacology/antibacterial_agents/macrolides.html
Tilmicosin is a macrolide antibiotic was prepared by chemical modifications of desmycosin, and is used in veterinary. It is recommended for treatment and prevention of pneumonia in cattle, sheep and pigs, associated with Pasteurella haemolytica, P. multocida, Actinobacillus pleuropneumoniae, mycoplasma species and other microorganisms found sensitive to this compound. Tilmicosin belongs to 16-membered ring group of class macrolides. The antimicrobial mechanism seems to be the same for all of the macrolides. They interfere with protein synthesis by reversibly binding to the 50S subunit of the ribosome. They appear to bind at the donor site, thus preventing the translocation necessary to keep the peptide chain growing. The effect is essentially confined to rapidly dividing bacteria and mycoplasmas. Macrolides are regarded as being bacteriostatic but demonstrate bactericidal activity at high concentrations.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3570967
Curator's Comment: A new macrolide antibiotic, EL-870, 20-deoxo-20-(3,5-dimethylpiperidin-1-yl)desmycosin, has been prepared by chemical modification of desmycosin
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | MICOTIL 300 Approved UseFor the treatment of bovine respiratory disease (BRD) and ovine respiratory disease (ORD) associated with Mannheimia (Pasteurella) haemolytica. For the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica. Launch Date2005 |
|||
Curative | MICOTIL 300 Approved UseFor the treatment of bovine respiratory disease (BRD) and ovine respiratory disease (ORD) associated with Mannheimia (Pasteurella) haemolytica. For the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica. Launch Date2005 |
PubMed
Title | Date | PubMed |
---|---|---|
Concentrations of tilmicosin in mammary gland secretions of dairy cows following subcutaneous administration of one or two doses of an experimental preparation of tilmicosin and its efficacy against intramammary infections caused by Staphylococcus aureus. | 2016 Sep |
Patents
Sample Use Guides
for animasl only: 10 mg/kg body weight (BW)(1.5 mL per 100 lb BW), administered once
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8787526
The MIC95 of TILMICOSIN for the Actinobacillus pleuropneumoniae isolates was 6.25 ug/mL while for the Pasteurella multocida isolates it was 12.5 ug/mL
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01FA91
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
||
|
CFR |
21 CFR 558.618
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
||
|
NCI_THESAURUS |
C261
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
||
|
CFR |
21 CFR 522.2471
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
||
|
CFR |
21 CFR 520.2471
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
||
|
CFR |
21 CFR 556.735
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
XL4103X2E3
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
100000082678
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
108050-54-0
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
C84213
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
6024
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
759584
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
TILMICOSIN
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
C052319
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
7446
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
m10866
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
X-93
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
5282521
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
SUB11054MIG
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
DB11471
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
XL4103X2E3
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
38278
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | RxNorm | ||
|
1667370
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908333
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY | |||
|
DTXSID5046011
Created by
admin on Fri Dec 15 18:45:05 GMT 2023 , Edited by admin on Fri Dec 15 18:45:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)